Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-versus-Tumor Effects

Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2

Bone Marrow Transplantation volume 44, pages 601–605 (2009)Cite this article

Abstract

The fludarabine (FLU)/melphalan (MEL) conditioning regimen containing FLU and high-dose MEL was analyzed in comparison with the BU/CY2 regimen to characterize oral mucositis (OM) and risk factors. OM incidence significantly varied between BU/CY2 and FLU/MEL (100 vs 78%, P=0.004), but the incidence of severe OM grades 3–4 WHO and kinetics of OM were fully comparable. Patients with OM persisting on day +21 had more acute GVHD (68 vs 32%, P=0.005), which tended to occur earlier than among those without such prolonged OM. Multivariate analysis showed significant dependency of acute GVHD on severity and prolonged duration of OM and significant correlation between OM severity and its prolonged duration. Body surface area-based dosing in the FLU/MEL regimen led to a wide range of MEL doses administered per kilogram body weight (2.5–5.2 mg/kg, median 3.5). In multivariate analysis, MEL dose per kilogram of body weight was found to be a significant predictor of OM incidence and severity. Female gender and lower body mass index were less important variables than the fact that the actual dose of MEL administered per kilogram of body weight was relatively high when the dosage was calculated on the basis of body surface area.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.

    Article  CAS  PubMed  Google Scholar 

  2. Kröger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919–3924.

    Article  PubMed  Google Scholar 

  3. Inamoto Y, Oba T, Miyamura K, Terakura S, Tsujimura A, Kuwatsuka Y et al. Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor. Int J Hematol 2006; 83: 356–362.

    Article  PubMed  Google Scholar 

  4. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno N et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M D. Anderson Cancer Center experience. Haematologica 2008; 93: 257–264.

    Article  CAS  PubMed  Google Scholar 

  5. Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 2005; 13: 266–269.

    Article  PubMed  Google Scholar 

  6. Woo SB, Sonis ST, Monopoli MM, Sonis AL . A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72: 1612–1617.

    Article  CAS  PubMed  Google Scholar 

  7. Sonis S, Oster G, Fuchs H . Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201–2205.

    Article  CAS  PubMed  Google Scholar 

  8. Gibson RJ, Bowen JM, Keefe DM . Technological advances in mucositis research: new insights and new issues. Cancer Treat Rev 2008; 34: 476–482.

    Article  PubMed  Google Scholar 

  9. Bolwell BJ, Kalaycio M, Sobecks R . A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 2002; 30: 587–591.

    Article  CAS  PubMed  Google Scholar 

  10. Robien K, Schubert M, Bruemmer B . Predictors of oral mucositis in patients receiving hematopoietic cell transplant for chronic myelogenous leukemia. J Clin Oncol 2004; 22: 1268–1275.

    Article  PubMed  Google Scholar 

  11. Montserrat VL, Sonis S, Oster G . Burden of oral mucositis and/or esophagitis in patients undergoing radiation treatment for head and neck cancer or non-small cell lung cancer. J Clin Oncol 2004; 22: 14S 8104.

    Article  Google Scholar 

  12. McCarthy GM, Awde JD, Ghandi H . Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 1998; 34: 484–490.

    Article  CAS  PubMed  Google Scholar 

  13. Rapoport AP, Miller Watelet LF, Linder T . Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplant. J Clin Oncol 1999; 17: 2446–2453.

    Article  CAS  PubMed  Google Scholar 

  14. Branda RF, Naud S, Brooks EM . Effect of vitamin B12, folate, and dietary supplements on breast carcinoma chemotherapy induced mucositis and neutropenia. Cancer 2004; 100: 1058–1064.

    Article  Google Scholar 

  15. Vokurka S, Bystricka E, Koza V . The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT—results of a randomized multicentre study. Support Care Cancer 2005; 13: 554–558.

    Article  PubMed  Google Scholar 

  16. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J et al. Prospective Oral Mucositis Audit: Oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European Blood and Marrow Transplantation Mucositis Advisory Group. J. Clin. Oncol 2008; 26: 1519–1525.

    Article  CAS  PubMed  Google Scholar 

  17. Rubenstein E, Peterson D, Schubert M . Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100: 2026–2046.

    Article  PubMed  Google Scholar 

  18. Cutler C, Laglenne P, Ford C, Ho V, Lee SJ, Alyea E et al. Oral Mucositis incidence and severity after methotrexate and non-methotrexate containing GVHD prophylaxis regimens. Blood (ASH Annu Meet Abstr) 2004; 104: 351.

    Google Scholar 

  19. Bolwell B, Sobecks R, Pohlman B . A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621–625.

    Article  CAS  PubMed  Google Scholar 

  20. Bensinger W, Schubert M, Ang KK . Task Force Report. Prevention and management of mucositis in cancer care. J Natl Compr Cancer Netw 2008; 6 (Suppl1): 1–21.

    Google Scholar 

  21. Chansky K, Benedetti J, Macdonald JS . Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005; 103: 1165–1171.

    Article  CAS  PubMed  Google Scholar 

  22. DuBois D, DuBois EF . A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863–871.

    Article  CAS  Google Scholar 

  23. Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006; 38: 501–506.

    Article  CAS  PubMed  Google Scholar 

  24. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  25. Devergie A . Graft versus host disease. In: J Apperley, E Carreras, E Gluckman, A Gratwohl, T Masszi (eds). The 2008 revised edition of the ESH-EBMT Handbook on Haemopoietic Stem Cell Transplantation. Forum-Service Editore, Genova, Italy, 2008, pp 219–234.

    Google Scholar 

  26. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haemato-Oncology, University Hospital in Plzen (Pilsen), Plzen (Pilsen), Czech Republic

    S Vokurka, K Steinerova, M Karas & V Koza

Authors
  1. S Vokurka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Steinerova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Karas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V Koza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Vokurka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vokurka, S., Steinerova, K., Karas, M. et al. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Bone Marrow Transplant 44, 601–605 (2009). https://doi.org/10.1038/bmt.2009.66

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.66

Keywords

This article is cited by

Search

Advanced search

Quick links